NL-OMON27212招募中不适用

The value of completion axillary treatment in sentinel node positive breast cancer patients undergoing a mastectomy (BOOG 2013-07).

Pink Ribbon, KWF0 个研究点目标入组 878 人开始时间: 待定最近更新: 2024年2月28日

研究概览

简要总结

.M. van Roozendaal, J.H.W. de Wilt, T. Van Dalen, J.A. van der Hage, L.J.A. Strobbe, L.J. Boersma, S.C. Linn, M.B.I Lobbes, P.M.P. Poortmans, V.C.G Tjan-Heijnen, K.K.B.T. van de Vijver, J. de Vries, A.H. Westenberg, A.G.H. Kessels, M.L. Smidt. The value of completion axillary treatment in sentinel node positive breast cancer patients undergonig a mastectomy: a Dutch randomized controlled multicentre trial (BOOG 2013-07). BMC Cancer (2015) 15:610 DOI 10.1186/s12885-015-1613-2.

研究设计

研究类型: Interventional

入排标准

入选标准

•2. Aged 18 years or older

排除标准

•1. Clinically node positive pre-operative
•2. Sentinel lymph nodes only containing isolated tumour cells (<0.2mm)

研究者

发起方

Pink Ribbon, KWF

相似试验

已完成

3 期

The value of completion axillary treatment in sentinel node positive breast cancer patients undergoing a mastectomy: a Dutch multicentre cohort study laxillaire lymfekliermetastasenaxillary lymph node metastasesnodal metastases1000629110006295breast cancer

NL-OMON44960Medisch Universitair Ziekenhuis Maastricht878

招募中

不适用

BOOG 2013-07: The value of completion axillary treatment in sentinel node positive breast cancer patients undergoing a mastectomy.breast neoplasmsaxillary lymph node dessctionmastectomy.breast cancer

NL-OMON29048Pink Ribbon, KWF, CZ878

终止

不适用

Omitting Completion Axillary Treatment in Sentinel Node Positive Breast Cancer Patients Undergoing a MastectomyBreast Neoplasms

NCT02112682Maastricht University Medical Center52

已完成

1 期

Axillary evaluation with targeted axillary dissection using ultrasound visible clips after neoadjuvant chemotherapy for patients with node-positive breast cancerbreast cancer

JPRN-UMIN000048884Breast Center, Kameda medical center26

尚未招募

Unknown

Tailored axillary surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (TAXIS). A multicenter randomized phase III trial. (OPBC-03/ SAKK 23/16 / IBCSG 57-18 / ABCSG-53 / GBG-101)Neoplasms

KCT0008996Yonsei University Health System, Gangnam Severance Hospital1,500